ID   AGM1_HUMAN              Reviewed;         542 AA.
AC   O95394; B2RB65; B4DX94; D6RF12; E1P547; E9PF86; Q5JWR4; Q96J46;
AC   Q9H8G5; Q9NS94; Q9NTT6; Q9UFV5; Q9UIY2;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   10-MAY-2017, entry version 177.
DE   RecName: Full=Phosphoacetylglucosamine mutase {ECO:0000305};
DE            Short=PAGM;
DE            EC=5.4.2.3 {ECO:0000269|PubMed:24589341, ECO:0000269|PubMed:24698316, ECO:0000269|PubMed:24931394};
DE   AltName: Full=Acetylglucosamine phosphomutase {ECO:0000305};
DE   AltName: Full=N-acetylglucosamine-phosphate mutase {ECO:0000303|PubMed:10721701};
DE   AltName: Full=Phosphoglucomutase-3 {ECO:0000312|HGNC:HGNC:8907};
DE            Short=PGM 3;
GN   Name=PGM3 {ECO:0000312|HGNC:HGNC:8907};
GN   Synonyms=AGM1 {ECO:0000303|PubMed:11004509};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Matthijs G., Schollen E., Dierickx D.;
RL   Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=10721701; DOI=10.1016/S0378-1119(99)00543-0;
RA   Li C., Rodriguez M., Banerjee D.;
RT   "Cloning and characterization of complementary DNA encoding human N-
RT   acetylglucosamine-phosphate mutase protein.";
RL   Gene 242:97-103(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), MUTAGENESIS, ACTIVE SITE, AND
RP   VARIANT ASN-466.
RX   PubMed=11004509; DOI=10.1016/S0167-4781(00)00120-2;
RA   Mio T., Yamada-Okabe T., Arisawa M., Yamada-Okabe H.;
RT   "Functional cloning and mutational analysis of the human cDNA for
RT   phosphoacetylglucosamine mutase: identification of the amino acid
RT   residues essential for the catalysis.";
RL   Biochim. Biophys. Acta 1492:369-376(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Placenta, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ASN-466.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 392-542 (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, INVOLVEMENT IN IMD23, VARIANTS
RP   IMD23 HIS-239; SER-246 AND ARG-451, AND CHARACTERIZATION OF VARIANTS
RP   IMD23 HIS-239; SER-246 AND ARG-451.
RX   PubMed=24931394; DOI=10.1016/j.ajhg.2014.05.007;
RG   Baylor-Johns Hopkins Center for Mendelian Genomics;
RA   Stray-Pedersen A., Backe P.H., Sorte H.S., Moerkrid L., Chokshi N.Y.,
RA   Erichsen H.C., Gambin T., Elgstoeen K.B., Bjoeraas M., Wlodarski M.W.,
RA   Krueger M., Jhangiani S.N., Muzny D.M., Patel A., Raymond K.M.,
RA   Sasa G.S., Krance R.A., Martinez C.A., Abraham S.M., Speckmann C.,
RA   Ehl S., Hall P., Forbes L.R., Merckoll E., Westvik J., Nishimura G.,
RA   Rustad C.F., Abrahamsen T.G., Roennestad A., Osnes L.T., Egeland T.,
RA   Roedningen O.K., Beck C.R., Boerwinkle E.A., Gibbs R.A., Lupski J.R.,
RA   Orange J.S., Lausch E., Hanson I.C.;
RT   "PGM3 mutations cause a congenital disorder of glycosylation with
RT   severe immunodeficiency and skeletal dysplasia.";
RL   Am. J. Hum. Genet. 95:96-107(2014).
RN   [18]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, INVOLVEMENT IN IMD23, VARIANTS
RP   IMD23 GLU-297 AND GLN-501, AND CHARACTERIZATION OF VARIANTS IMD23
RP   GLU-297 AND GLN-501.
RX   PubMed=24589341; DOI=10.1016/j.jaci.2014.02.013;
RA   Zhang Y., Yu X., Ichikawa M., Lyons J.J., Datta S., Lamborn I.T.,
RA   Jing H., Kim E.S., Biancalana M., Wolfe L.A., DiMaggio T.,
RA   Matthews H.F., Kranick S.M., Stone K.D., Holland S.M., Reich D.S.,
RA   Hughes J.D., Mehmet H., McElwee J., Freeman A.F., Freeze H.H.,
RA   Su H.C., Milner J.D.;
RT   "Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link
RT   glycosylation defects to atopy, immune deficiency, autoimmunity, and
RT   neurocognitive impairment.";
RL   J. Allergy Clin. Immunol. 133:1400-1409(2014).
RN   [19]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, INVOLVEMENT IN IMD23, VARIANTS
RP   IMD23 SER-83; GLU-340 DEL AND TYR-502, AND CHARACTERIZATION OF
RP   VARIANTS IMD23 SER-83; GLU-340 DEL AND TYR-502.
RX   PubMed=24698316; DOI=10.1016/j.jaci.2014.02.025;
RA   Sassi A., Lazaroski S., Wu G., Haslam S.M., Fliegauf M., Mellouli F.,
RA   Patiroglu T., Unal E., Ozdemir M.A., Jouhadi Z., Khadir K.,
RA   Ben-Khemis L., Ben-Ali M., Ben-Mustapha I., Borchani L., Pfeifer D.,
RA   Jakob T., Khemiri M., Asplund A.C., Gustafsson M.O., Lundin K.E.,
RA   Falk-Soerqvist E., Moens L.N., Gungor H.E., Engelhardt K.R.,
RA   Dziadzio M., Stauss H., Fleckenstein B., Meier R., Prayitno K.,
RA   Maul-Pavicic A., Schaffer S., Rakhmanov M., Henneke P., Kraus H.,
RA   Eibel H., Koelsch U., Nadifi S., Nilsson M., Bejaoui M.,
RA   Schaeffer A.A., Smith C.I., Dell A., Barbouche M.R., Grimbacher B.;
RT   "Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3)
RT   impair immunity and increase serum IgE levels.";
RL   J. Allergy Clin. Immunol. 133:1410-1419(2014).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-62 AND SER-64, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   VARIANT ASN-466.
RX   PubMed=12174217; DOI=10.1046/j.1469-1809.2002.00103.x;
RA   Pang H., Koda Y., Soejima M., Kimura H.;
RT   "Identification of human phosphoglucomutase 3 (PGM3) as N-
RT   acetylglucosamine-phosphate mutase (AGM1).";
RL   Ann. Hum. Genet. 66:139-144(2002).
CC   -!- FUNCTION: Catalyzes the conversion of GlcNAc-6-P into GlcNAc-1-P
CC       during the synthesis of uridine diphosphate/UDP-GlcNAc, a sugar
CC       nucleotide critical to multiple glycosylation pathways including
CC       protein N- and O-glycosylation. {ECO:0000303|PubMed:24589341,
CC       ECO:0000303|PubMed:24698316, ECO:0000303|PubMed:24931394}.
CC   -!- CATALYTIC ACTIVITY: N-acetyl-alpha-D-glucosamine 1-phosphate = N-
CC       acetyl-D-glucosamine 6-phosphate. {ECO:0000269|PubMed:24589341,
CC       ECO:0000269|PubMed:24698316, ECO:0000269|PubMed:24931394}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:Q9P4V2};
CC       Note=Binds 1 Mg(2+) ion per subunit.
CC       {ECO:0000250|UniProtKB:Q9P4V2};
CC   -!- PATHWAY: Nucleotide-sugar biosynthesis; UDP-N-acetyl-alpha-D-
CC       glucosamine biosynthesis; N-acetyl-alpha-D-glucosamine 1-phosphate
CC       from alpha-D-glucosamine 6-phosphate (route I): step 2/2.
CC       {ECO:0000303|PubMed:24589341, ECO:0000303|PubMed:24698316,
CC       ECO:0000303|PubMed:24931394}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O95394-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O95394-3; Sequence=VSP_047320;
CC         Note=Gene prediction based on EST data.;
CC       Name=3;
CC         IsoId=O95394-4; Sequence=VSP_047319;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Found in many tissues except lung. Relatively
CC       high expression in pancreas, heart, liver, and placenta, and
CC       relatively low expression in brain, skeletal muscle and kidney.
CC       {ECO:0000269|PubMed:10721701}.
CC   -!- DISEASE: Immunodeficiency 23 (IMD23) [MIM:615816]: A primary
CC       immunodeficiency syndrome characterized by recurrent respiratory
CC       and skin infections beginning in early childhood, severe atopy,
CC       increased serum IgE, and developmental delay or cognitive
CC       impairment of varying severity. {ECO:0000269|PubMed:24589341,
CC       ECO:0000269|PubMed:24698316, ECO:0000269|PubMed:24931394}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the phosphohexose mutase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB14652.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF102265; AAC72409.1; -; mRNA.
DR   EMBL; AF180371; AAD55097.1; -; mRNA.
DR   EMBL; AB032081; BAB00613.1; -; mRNA.
DR   EMBL; AK023709; BAB14652.1; ALT_INIT; mRNA.
DR   EMBL; AK301867; BAG63306.1; -; mRNA.
DR   EMBL; AK314512; BAG37112.1; -; mRNA.
DR   EMBL; AL049699; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL121716; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW48670.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48671.1; -; Genomic_DNA.
DR   EMBL; BC001258; AAH01258.1; -; mRNA.
DR   EMBL; AL117443; CAB55928.1; -; mRNA.
DR   CCDS; CCDS4997.1; -. [O95394-1]
DR   CCDS; CCDS56435.1; -. [O95394-3]
DR   CCDS; CCDS56436.1; -. [O95394-4]
DR   PIR; T17238; T17238.
DR   RefSeq; NP_001186846.1; NM_001199917.1. [O95394-4]
DR   RefSeq; NP_001186848.1; NM_001199919.1. [O95394-3]
DR   RefSeq; NP_056414.1; NM_015599.2. [O95394-1]
DR   RefSeq; XP_016866425.1; XM_017010936.1. [O95394-3]
DR   UniGene; Hs.661665; -.
DR   ProteinModelPortal; O95394; -.
DR   SMR; O95394; -.
DR   BioGrid; 111257; 14.
DR   IntAct; O95394; 1.
DR   MINT; MINT-5000376; -.
DR   STRING; 9606.ENSP00000425809; -.
DR   iPTMnet; O95394; -.
DR   PhosphoSitePlus; O95394; -.
DR   BioMuta; PGM3; -.
DR   EPD; O95394; -.
DR   MaxQB; O95394; -.
DR   PaxDb; O95394; -.
DR   PeptideAtlas; O95394; -.
DR   PRIDE; O95394; -.
DR   DNASU; 5238; -.
DR   Ensembl; ENST00000506587; ENSP00000425809; ENSG00000013375. [O95394-4]
DR   Ensembl; ENST00000512866; ENSP00000421565; ENSG00000013375. [O95394-3]
DR   Ensembl; ENST00000513973; ENSP00000424874; ENSG00000013375. [O95394-1]
DR   GeneID; 5238; -.
DR   KEGG; hsa:5238; -.
DR   UCSC; uc003pju.3; human. [O95394-1]
DR   CTD; 5238; -.
DR   DisGeNET; 5238; -.
DR   GeneCards; PGM3; -.
DR   HGNC; HGNC:8907; PGM3.
DR   HPA; CAB004998; -.
DR   HPA; HPA029759; -.
DR   HPA; HPA029760; -.
DR   MalaCards; PGM3; -.
DR   MIM; 172100; gene.
DR   MIM; 615816; phenotype.
DR   neXtProt; NX_O95394; -.
DR   OpenTargets; ENSG00000013375; -.
DR   PharmGKB; PA33244; -.
DR   eggNOG; KOG2537; Eukaryota.
DR   eggNOG; COG1109; LUCA.
DR   GeneTree; ENSGT00390000000509; -.
DR   HOGENOM; HOG000210027; -.
DR   HOVERGEN; HBG024321; -.
DR   InParanoid; O95394; -.
DR   KO; K01836; -.
DR   OMA; EPFTRCV; -.
DR   OrthoDB; EOG091G065D; -.
DR   PhylomeDB; O95394; -.
DR   TreeFam; TF105670; -.
DR   BioCyc; MetaCyc:HS00347-MONOMER; -.
DR   BRENDA; 5.4.2.3; 2681.
DR   Reactome; R-HSA-446210; Synthesis of UDP-N-acetyl-glucosamine.
DR   SABIO-RK; O95394; -.
DR   UniPathway; UPA00113; UER00530.
DR   ChiTaRS; PGM3; human.
DR   GeneWiki; Phosphoglucomutase_3; -.
DR   GenomeRNAi; 5238; -.
DR   PRO; PR:O95394; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000013375; -.
DR   CleanEx; HS_PGM3; -.
DR   ExpressionAtlas; O95394; baseline and differential.
DR   Genevisible; O95394; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004610; F:phosphoacetylglucosamine mutase activity; IDA:UniProtKB.
DR   GO; GO:0004614; F:phosphoglucomutase activity; IEA:Ensembl.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0006041; P:glucosamine metabolic process; NAS:UniProtKB.
DR   GO; GO:0019255; P:glucose 1-phosphate metabolic process; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; IBA:GO_Central.
DR   GO; GO:0006487; P:protein N-linked glycosylation; IMP:UniProtKB.
DR   GO; GO:0006493; P:protein O-linked glycosylation; IMP:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0006048; P:UDP-N-acetylglucosamine biosynthetic process; IMP:UniProtKB.
DR   CDD; cd03086; PGM3; 1.
DR   Gene3D; 3.30.310.50; -; 1.
DR   InterPro; IPR005844; A-D-PHexomutase_a/b/a-I.
DR   InterPro; IPR016055; A-D-PHexomutase_a/b/a-I/II/III.
DR   InterPro; IPR005843; A-D-PHexomutase_C.
DR   InterPro; IPR016066; A-D-PHexomutase_CS.
DR   InterPro; IPR016657; PAGM.
DR   Pfam; PF02878; PGM_PMM_I; 2.
DR   Pfam; PF00408; PGM_PMM_IV; 1.
DR   PIRSF; PIRSF016408; PAGM; 1.
DR   SUPFAM; SSF53738; SSF53738; 3.
DR   SUPFAM; SSF55957; SSF55957; 1.
DR   PROSITE; PS00710; PGM_PMM; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Carbohydrate metabolism;
KW   Complete proteome; Disease mutation; Isomerase; Magnesium;
KW   Metal-binding; Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN         1    542       Phosphoacetylglucosamine mutase.
FT                                /FTId=PRO_0000148013.
FT   REGION      370    372       Substrate binding.
FT                                {ECO:0000250|UniProtKB:Q9P4V2}.
FT   REGION      496    500       Substrate binding.
FT                                {ECO:0000250|UniProtKB:Q9P4V2}.
FT   ACT_SITE     64     64       Phosphoserine intermediate.
FT                                {ECO:0000303|PubMed:11004509}.
FT   METAL        64     64       Magnesium; via phosphate group.
FT                                {ECO:0000250|UniProtKB:Q9P4V2}.
FT   METAL       276    276       Magnesium.
FT                                {ECO:0000250|UniProtKB:Q9P4V2}.
FT   METAL       278    278       Magnesium.
FT                                {ECO:0000250|UniProtKB:Q9P4V2}.
FT   METAL       280    280       Magnesium.
FT                                {ECO:0000250|UniProtKB:Q9P4V2}.
FT   BINDING     505    505       Substrate.
FT                                {ECO:0000250|UniProtKB:Q9P4V2}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895}.
FT   MOD_RES      62     62       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      64     64       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1      1       M -> MGGEWGQSAICPESAQEWTYQVGQHLVDM (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_047319.
FT   VAR_SEQ     542    542       F -> YKAAETTHNINNAFGPGTANEHTVP (in
FT                                isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_047320.
FT   VARIANT      83     83       L -> S (in IMD23; decreased
FT                                phosphoacetylglucosamine mutase activity;
FT                                no effect on protein abundance;
FT                                dbSNP:rs267608260).
FT                                {ECO:0000269|PubMed:24698316}.
FT                                /FTId=VAR_071359.
FT   VARIANT     239    239       D -> H (in IMD23; decreased
FT                                phosphoacetylglucosamine mutase
FT                                activity). {ECO:0000269|PubMed:24931394}.
FT                                /FTId=VAR_071360.
FT   VARIANT     246    246       N -> S (in IMD23; loss of
FT                                phosphoacetylglucosamine mutase activity;
FT                                dbSNP:rs587777562).
FT                                {ECO:0000269|PubMed:24931394}.
FT                                /FTId=VAR_071361.
FT   VARIANT     297    297       D -> E (in IMD23; decreased
FT                                phosphoacetylglucosamine mutase activity;
FT                                decreased protein abundance;
FT                                dbSNP:rs587777415).
FT                                {ECO:0000269|PubMed:24589341}.
FT                                /FTId=VAR_071362.
FT   VARIANT     340    340       Missing (in IMD23; decreased
FT                                phosphoacetylglucosamine mutase activity;
FT                                decreased protein abundance).
FT                                {ECO:0000269|PubMed:24698316}.
FT                                /FTId=VAR_071363.
FT   VARIANT     451    451       Q -> R (in IMD23; decreased
FT                                phosphoacetylglucosamine mutase activity;
FT                                dbSNP:rs587777565).
FT                                {ECO:0000269|PubMed:24931394}.
FT                                /FTId=VAR_071364.
FT   VARIANT     466    466       D -> N (in allele PGM3*2;
FT                                dbSNP:rs473267).
FT                                {ECO:0000269|PubMed:11004509,
FT                                ECO:0000269|PubMed:12174217,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_013489.
FT   VARIANT     501    501       E -> Q (in IMD23; decreased
FT                                phosphoacetylglucosamine mutase activity;
FT                                no effect on protein abundance;
FT                                dbSNP:rs587777413).
FT                                {ECO:0000269|PubMed:24589341}.
FT                                /FTId=VAR_071365.
FT   VARIANT     502    502       D -> Y (in IMD23; decreased
FT                                phosphoacetylglucosamine mutase activity;
FT                                no effect on protein abundance;
FT                                dbSNP:rs267608261).
FT                                {ECO:0000303|PubMed:24698316}.
FT                                /FTId=VAR_071366.
FT   MUTAGEN      64     64       S->A: Loss of activity.
FT                                {ECO:0000269|PubMed:11004509}.
FT   MUTAGEN      65     65       H->A: Loss of activity.
FT                                {ECO:0000269|PubMed:11004509}.
FT   MUTAGEN     278    278       D->A,E: Loss of activity.
FT                                {ECO:0000269|PubMed:11004509}.
FT   MUTAGEN     281    281       R->A,K: Loss of activity.
FT                                {ECO:0000269|PubMed:11004509}.
FT   CONFLICT      5      5       A -> V (in Ref. 4; BAG63306).
FT                                {ECO:0000305}.
FT   CONFLICT     70     70       D -> G (in Ref. 4; BAG63306).
FT                                {ECO:0000305}.
SQ   SEQUENCE   542 AA;  59852 MW;  6A4FBCD99A2154A9 CRC64;
     MDLGAITKYS ALHAKPNGLI LQYGTAGFRT KAEHLDHVMF RMGLLAVLRS KQTKSTIGVM
     VTASHNPEED NGVKLVDPLG EMLAPSWEEH ATCLANAEEQ DMQRVLIDIS EKEAVNLQQD
     AFVVIGRDTR PSSEKLSQSV IDGVTVLGGQ FHDYGLLTTP QLHYMVYCRN TGGRYGKATI
     EGYYQKLSKA FVELTKQASC SGDEYRSLKV DCANGIGALK LREMEHYFSQ GLSVQLFNDG
     SKGKLNHLCG ADFVKSHQKP PQGMEIKSNE RCCSFDGDAD RIVYYYHDAD GHFHLIDGDK
     IATLISSFLK ELLVEIGESL NIGVVQTAYA NGSSTRYLEE VMKVPVYCTK TGVKHLHHKA
     QEFDIGVYFE ANGHGTALFS TAVEMKIKQS AEQLEDKKRK AAKMLENIID LFNQAAGDAI
     SDMLVIEAIL ALKGLTVQQW DALYTDLPNR QLKVQVADRR VISTTDAERQ AVTPPGLQEA
     INDLVKKYKL SRAFVRPSGT EDVVRVYAEA DSQESADHLA HEVSLAVFQL AGGIGERPQP
     GF
//
